Biologics Are Going Through an Identity Crisis (reprise)
So, can you easily explain the differences between a chemically synthesized drug and a biologic? You might be surprised how difficult that has become. The
January 3, 2023
So, can you easily explain the differences between a chemically synthesized drug and a biologic? You might be surprised how difficult that has become. The
We know that there are a limited number of specialty pharmacies in the US. A small number of customers makes it hard for any new product
The FDA recently approved a novel, ORAL monotherapy treatment, Rezlidhia (olutasidenib) from Rigel Pharmaceuticals, Inc., to treat adult patients with relapsed or refractory (R/R) acute
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
Rigel Pharmaceuticals recently received the green light from the FDA for their oral IDH1 inhibitor, REZLIDHIA™ (olutasidenib). REZLIDHIA™ is indicated for treatment of acute myeloid
Whoa….. we missed covering this FDA approval. Way back in October the FDA approved a new subcutaneous treatment, Tecvayli from Janssen Biotech, for adult patients
In the spirit of continuing to elevate our client offerings, services and experiences Anton Health is proud to welcome Tara Mautone as the Executive Director
Optum is turning to technology to bring down special infusion spend. Others have tried a variety of ideas to achieve this goal going back to the
It has finally happened….. the decades’ long wait for the approval of the holy grail in hemophilia treatment….. a gene therapy that replaces the need for
The FDA recently approved a new infused therapy, Elahere (mirvetuximab soravtansine-gynx) from ImmunoGen Inc., indicated for the treatment of adult patients with folate receptor alpha
